Delving into the Latest Updates on Xin Ling Yi Yao （ Zhong Shan ） You Xian Gong Si with Synapse

Overview

Tags

Other Diseases

Nervous System Diseases

Endocrinology and Metabolic Disease

Small molecule drug

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Neoplasms	1
Endocrinology and Metabolic Disease	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	6
Chemical drugs	1

预评估受试制剂诺孕曲明炔雌醇贴片（规格：诺孕曲明150 μg/天；炔雌醇35 μg/天）与参比制剂XULANE®（规格：诺孕曲明150 μg/天；炔雌醇35μg/天）在健康女性参与者外用条件下的单中心、开放、随机、单剂量、三周期、六序列、交叉生物等效性和黏附力试验

[Translation] A single-center, open-label, randomized, single-dose, three-period, six-sequence, crossover bioequivalence and adhesion study to evaluate the test preparation, norelgestromin ethinyl estradiol patch (strength: norelgestromin 150 μg/day; ethinyl estradiol 35 μg/day) and the reference preparation, XULANE® (strength: norelgestromin 150 μg/day; ethinyl estradiol 35 μg/day), in healthy female participants under topical conditions

主要试验目的：研究外用条件下单次给予受试制剂诺孕曲明炔雌醇贴片（规格：诺孕曲明150 μg/天；炔雌醇35 μg/天，新领医药技术（深圳）有限公司生产）与参比制剂XULANE®（规格：诺孕曲明150 μg/天；炔雌醇35μg/天；持证商Mylan Technologies Inc.）在健康女性参与者体内的药代动力学特征和黏附力，为正式人体生物等效性和黏附力试验提供参考。次要试验目的：研究受试制剂诺孕曲明炔雌醇贴片（规格：诺孕曲明150 μg/天；炔雌醇35 μg/天）和参比制剂XULANE®（规格：诺孕曲明150μg/天；炔雌醇35 μg/天）在健康参与者中的安全性。

[Translation]

The main purpose of the study is to study the pharmacokinetic characteristics and adhesion of the test preparation norgestromin ethinyl estradiol patch (specifications: norgestromin 150 μg/day; ethinyl estradiol 35 μg/day, produced by Xinling Pharmaceutical Technology (Shenzhen) Co., Ltd.) and the reference preparation XULANE® (specifications: norgestromin 150 μg/day; ethinyl estradiol 35 μg/day; licensee Mylan Technologies Inc.) in healthy female participants after single administration under topical conditions, so as to provide a reference for formal human bioequivalence and adhesion tests. Secondary purpose of the study is to study the safety of the test preparation norgestromin ethinyl estradiol patch (specifications: norgestromin 150 μg/day; ethinyl estradiol 35 μg/day) and the reference preparation XULANE® (specifications: norgestromin 150 μg/day; ethinyl estradiol 35 μg/day) in healthy participants.

Start Date-

Sponsor / Collaborator

Xin Ling Yi Yao （ Zhong Shan ） You Xian Gong Si

CTR20233569

/ CompletedNot Applicable

预评估受试制剂雌二醇贴片（规格：0.1 mg/天）与参比制剂Vivelle-Dot®（规格：0.1 mg/天）在健康绝经后女性参与者外用条件下的单中心、开放、随机、单剂量、两周期、两序列、交叉生物等效性和黏附力试验

[Translation] A single-center, open-label, randomized, single-dose, two-period, two-sequence, crossover bioequivalence and adhesion study to preliminarily evaluate the test preparation estradiol patch (strength: 0.1 mg/day) and the reference preparation Vivelle-Dot® (strength: 0.1 mg/day) in healthy postmenopausal female participants under topical conditions

主要试验目的：研究外用条件下单次给予受试制剂雌二醇贴片（规格：0.1 mg/天，新领医药（中山）有限公司生产）与参比制剂Vivelle-Dot®（规格：0.1 mg/天；Noven Pharmaceuticals Inc.生产）在健康绝经后女性参与者体内的药代动力学特征和黏附力，为正式人体生物等效性和黏附力试验提供参考。次要试验目的：研究受试制剂雌二醇贴片（规格：0.1 mg/天）和参比制剂Vivelle-Dot®（规格：0.1 mg/天）在健康绝经后女性参与者中的安全性。

[Translation]

The main purpose of the study is to study the pharmacokinetic characteristics and adhesion of the test preparation estradiol patch (specification: 0.1 mg/day, produced by Xinling Pharmaceutical (Zhongshan) Co., Ltd.) and the reference preparation Vivelle-Dot® (specification: 0.1 mg/day; produced by Noven Pharmaceuticals Inc.) in healthy postmenopausal female participants after a single administration under topical conditions, to provide a reference for formal human bioequivalence and adhesion tests. Secondary purpose of the study: to study the safety of the test preparation estradiol patch (specification: 0.1 mg/day) and the reference preparation Vivelle-Dot® (specification: 0.1 mg/day) in healthy postmenopausal female participants.

Start Date29 Nov 2023

Sponsor / Collaborator

Xin Ling Yi Yao （ Zhong Shan ） You Xian Gong Si

CTR20223105

/ CompletedNot Applicable

预评估受试制剂罗替高汀贴片（规格：4.5 mg/10 cm2 （释药量 2 mg/24 h））与参比制剂罗替高汀贴片（优普洛®，规格：2 mg/24 h）在健康成年受试者外用条件下的单中心、开放、随机、单剂量、两周期、四序列、交叉生物等效性和黏附力研究

[Translation] A single-center, open-label, randomized, single-dose, two-period, four-sequence, crossover bioequivalence and adhesion study to evaluate the bioequivalence of the test product, rotigotine patch (strength: 4.5 mg/10 cm2 (release 2 mg/24 h)) and the reference product, rotigotine patch (Upro®, strength: 2 mg/24 h), in healthy adult subjects under topical conditions

主要试验目的：研究外用条件下单次给予受试制剂罗替高汀贴片（规格：4.5 mg/10 cm2（释药量2 mg/24 h））与参比制剂罗替高汀贴片（优普洛®，规格：2 mg/24 h）在健康受试者体内的药代动力学特征和黏附力，为正式人体生物等效性和黏附力研究提供参考。次要试验目的：研究受试制剂罗替高汀贴片（规格：4.5 mg/10 cm2（释药量2 mg/24 h））和参比制剂罗替高汀贴片（优普洛®）（规格：2 mg/24 h）在健康受试者中的安全性。

[Translation]

Main purpose of the study: To study the pharmacokinetic characteristics and adhesion of the test preparation Rotigotine patch (specification: 4.5 mg/10 cm2 (drug release 2 mg/24 h)) and the reference preparation Rotigotine patch (Upro®, specification: 2 mg/24 h) in healthy subjects after single administration under topical conditions, and to provide a reference for formal human bioequivalence and adhesion studies. Secondary purpose of the study: To study the safety of the test preparation Rotigotine patch (specification: 4.5 mg/10 cm2 (drug release 2 mg/24 h)) and the reference preparation Rotigotine patch (Upro®) (specification: 2 mg/24 h) in healthy subjects.

Start Date04 Jan 2023

Sponsor / Collaborator

Novastage Pharmaceuticals (shenzhen) Ltd.

100 Clinical Results associated with Xin Ling Yi Yao （ Zhong Shan ） You Xian Gong Si

Login to view more data

0 Patents (Medical) associated with Xin Ling Yi Yao （ Zhong Shan ） You Xian Gong Si

Login to view more data

100 Deals associated with Xin Ling Yi Yao （ Zhong Shan ） You Xian Gong Si

Login to view more data

100 Translational Medicine associated with Xin Ling Yi Yao （ Zhong Shan ） You Xian Gong Si

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 18 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

3

2

Preclinical

IND Application

1

Phase 1 Clinical

Other

6

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

NOVA-1010	Sedation More	Phase 1
NS1009	-	IND Application
NOVA-1001	Sedation More	Preclinical
NOVA-1006	Migraine Disorders More	Preclinical
NOVA-1003	Neoplasms More	Discovery